首页

Zhaoke Ophthalmology Achieves Positive Topline Results from the Phase III Clinical Trial of TAB014 for wAMD

2025-01-02

1513

Zhaoke Ophthalmology Receives Regulatory Approval to Commercialize Three further Drugs in its Glaucoma Portfolio

2024-12-09

1492

Zhaoke Ophthalmology Achieves Positive Topline Results from the Two-Year Phase III Clinical Trial of its Myopia Drug NVK002

2024-10-23

1917

Zhaoke Ophthalmology Completes the Last Patient Last Visit in its Phase III Clinical Trial of TAB014 in China

2024-09-26

1360

Zhaoke Ophthalmology’s Bimatoprost Eye Drop (晶贝清®) Obtains Regulatory Approval for Commercialization

2024-09-20

1918

首页 1 2 3 4 5 尾页

Guangzhou Headquarters

Tel: 020-39062828

E-mail: info@zkoph.com

Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou

Hong Kong Headquarters

Tel: (852)23145100

E-mail: info@zkoph.com

Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong

Wechat

Guangzhou Headquarters

Tel: 020-39062888

E-mail: info@zkoph.com

Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou

Hong Kong Headquarters

Tel: (852)23145100

E-mail: info@zkoph.com

Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong

Wechat